Txl Active Wart Remover Pads

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of common warts, which are characterized by their rough, 'cauliflower-like' surface appearance.

Limitations of Use: There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed, and it is recommended to soak the wart in warm water for approximately 5 minutes. After soaking, the area must be dried thoroughly to ensure proper adhesion of the medicated plaster.

To apply the medicated plaster, healthcare professionals should first remove the bandage strips by peeling the backing off. If necessary, the medicated patch may be cut to fit the size of the wart. The plaster should then be carefully applied to the wart.

This procedure should be repeated every 48 hours as needed, continuing until the wart is removed, with a maximum treatment duration of up to 12 weeks.

Contraindications

Use is contraindicated in the following situations:

• Application on irritated, infected, or reddened skin is prohibited due to the potential for exacerbation of the condition.

• The product should not be applied to genital warts or warts located on the face, as these areas may require specialized treatment.

• Use is contraindicated on moles, birthmarks, and warts with hair growing from them to avoid complications or adverse reactions.

• Application to mucous membranes is not recommended, as it may lead to irritation or other adverse effects.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to consult a physician prior to use if they have diabetes or experience poor blood circulation, as these conditions may increase the risk of adverse effects.

In the event of accidental ingestion, immediate medical assistance should be sought, or the local Poison Control Center should be contacted without delay.

Patients should be instructed to discontinue use and contact their healthcare provider if any of the following conditions are present: irritated, infected, or reddened skin; genital warts; warts located on the face; moles; birthmarks; or warts with hair growing from them. Additionally, this product should not be applied to mucous membranes, as this may lead to unwanted complications.

Side Effects

Patients should be aware that the product is intended for external use only. Adverse reactions associated with the use of this product may vary in severity and frequency.

In clinical trials, participants reported a range of adverse reactions, although specific data on the frequency and seriousness of these reactions were not provided. Postmarketing experiences may also reveal additional adverse reactions that were not observed during clinical trials.

Healthcare professionals are encouraged to monitor patients for any unexpected reactions and report them accordingly.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Txl Active Wart Remover Pads (wart remover pads). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients should be aware that the safety of this medication during pregnancy has not been established. There are no available data regarding the potential risks or fetal outcomes associated with the use of this medication in pregnant individuals. Healthcare professionals are advised to consider the lack of information when prescribing this medication to women of childbearing potential and to discuss the potential risks and benefits with their patients. It is recommended that healthcare providers exercise caution and evaluate the necessity of treatment in pregnant patients.

Lactation

There is no specific information regarding the use of this drug in lactating mothers or any lactation considerations provided in the drug insert. Therefore, healthcare professionals should exercise caution when prescribing this medication to nursing mothers, as the effects on breastfed infants are not established.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. In the absence of documented overdosage data, healthcare professionals are advised to exercise caution and monitor patients closely for any unusual symptoms or adverse effects that may arise following administration.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Continuous monitoring of the patient's vital signs and clinical status is essential. If symptoms of overdosage are observed, appropriate interventions should be implemented based on the clinical presentation.

Healthcare professionals should also consider contacting a poison control center or a medical toxicologist for guidance on management strategies tailored to the specific situation. It is crucial to document any overdosage incidents thoroughly and report them to the relevant regulatory authorities to enhance the understanding of the medication's safety profile.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to elucidate these aspects of nonclinical toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to instruct patients not to apply the product on irritated, infected, or reddened skin, as well as to avoid use on genital warts, facial warts, moles, birthmarks, and warts with hair growing from them. Additionally, patients should be informed that the product should not be used on mucous membranes.

Providers should also recommend that patients consult with a healthcare professional before using the product if they have diabetes or poor blood circulation, ensuring that any potential risks are adequately addressed.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product within a temperature range of 59° to 86°F (15° to 30°C) to maintain its integrity and efficacy. Proper storage conditions must be adhered to, ensuring that the product is kept in a suitable container that protects it from environmental factors. Special handling requirements should be observed to prevent any compromise to the product's quality.

Additional Clinical Information

Patients should be advised to consult a healthcare professional prior to use if they have diabetes or poor blood circulation. No further information is available regarding laboratory tests, abuse potential, route, method, frequency of administration, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Txl Active Wart Remover Pads, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)